TARSUS PHARMACEUTICALS, INC. Cost of Revenue
TARSUS PHARMACEUTICALS, INC. (TARS) reported Cost of Revenue of $12.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $12.11M, a 94.21% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $9.40M, a 80.31% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-06-30 was $6.24M.
- TARSUS PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-03-31 was $5.21M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month |
|---|---|---|---|
| 2026-06-30 | $12.11M 10-Q · filed 2026-08-06 | $21.51M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $9.40M 10-Q · filed 2026-05-06 | ||
| 2025-06-30 | $6.24M 10-Q · filed 2026-08-06 | $11.45M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $5.21M 10-Q · filed 2026-05-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | $522.00K derived: sum of 2 quarters · filed 2023-08-10 | $555.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $522.00K 10-Q · filed 2023-08-10 | $555.00K 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $33.00K 10-Q · filed 2023-05-09 | ||
| 2021-09-30 | $65.00K 10-Q · filed 2022-11-09 | $2.10M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |